in vivo News and Research

RSS

Heart research news and updates from University of Houston

Matters of the heart dominate in February with Valentine's Day and the American Heart Association's 'Heart Month' topping the list. As you consider story ideas ranging from heart disease to relationships, keep in mind these resources from the University of Houston.

23 Jan 2010

Injectable sealant found to be biocompatible and effective for fetal tissue repair

A sealant inspired by mussels' ability to stick to surfaces under wet conditions has shown promise in the repair of defects in human fetal membranes, according to a recent Northwestern University study.

23 Jan 2010

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

BioTech Medics, Inc. announced today that they have begun the pre-production stage of creating two minute, sixty second and thirty second direct response TV and radio commercials for nationwide distribution for its proprietary SHBAN™ Alcohol Free Antiseptic Hand Sanitizer.

22 Jan 2010

The American Journal of Pathology: Highlights from February 2010 issue

A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology.

22 Jan 2010

Researchers show how MRSA transmission can be tracked in hospital settings

For the first time, researchers have shown how transmission of MRSA from one person to another can be precisely tracked in a hospital setting. The team have developed a remarkable new method that can 'zoom' from large-scale inter-continental transmission events to the much finer detail of person-to-person infection of MRSA within a single hospital.

22 Jan 2010

Molecular image guided system for diagnosis and treatment of small-cell peripheral lung cancer

Scientists at The Methodist Hospital Research Institute in Houston received a research grant from the Cancer Prevention Research Institute of Texas (CPRIT) today to develop the first molecular image guided system to diagnose and treat small-cell peripheral lung cancer in one sitting.

22 Jan 2010

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

In a significant step toward restoring healthy blood circulation to treat a variety of diseases, a team of scientists at Weill Cornell Medical College has developed a new technique and described a novel mechanism for turning human embryonic and pluripotent stem cells into plentiful, functional endothelial cells, which are critical to the formation of blood vessels.

21 Jan 2010

Growth of OMI equipment sales to reach $400M in 2014

In vivo optical molecular imaging (OMI) is poised to move into clinical use as one of the key tools in personalized medicine, complementing more established imaging tools such as CT and MRI. Growth of equipment sales is on track to reach $400 million in 2014 and nearly $1 billion by the end of the decade.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce the issuance of Patent No. 2003284385 entitled "Compositions and methods for enzymatic detachment of bacterial and fungal biofilms" by IP Australia (Australian Patent and Trademark Office).

21 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

Copper-free version of click chemistry crafted to create biomolecular probes

For the first time, the widely used molecular synthesis technique known as click chemistry has been safely applied to a living organism. Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have crafted a unique copper-free version of click chemistry to create biomolecular probes for in vivo studies of live mice. Conventional click chemistry reactions require a copper catalyst that is toxic to cells and organisms.

20 Jan 2010

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the publication of new data in the journal Nature Biotechnology by Alnylam scientists and collaborators from Tekmira Pharmaceuticals Corporation, AlCana Technologies, Inc., and The University of British Columbia (UBC). The new study employed a rational design approach for the discovery of novel lipids that can be incorporated into lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

20 Jan 2010

InVivo Therapeutics sponsors fundraising event to support patients with spinal cord injuries

InVivo Therapeutics will be the lead champion level sponsor for the black tie gala fundraiser to support the Greater Boston Chapter of the National Spinal Cord Injury Association, a non-profit organization that offers programs and services to those with spinal cord injury/disease (SCI).

20 Jan 2010

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that new pre-clinical data using proprietary rxRNA™ compounds was presented at the Keystone Symposia’s RNA Silencing: Mechanism, Biology and Application held January 14-19 in Keystone, Colorado.

20 Jan 2010

Fc engineering enhances antibody half-life

A Nature Biotechnology article published online January 17 reveals that Xencor Inc.’s proprietary Fc engineering extends the half-life of antibodies while maintaining their potency and extending duration of action. These results, published in an article entitled, “Enhanced antibody half-life improves in vivo activity” demonstrate the potential of Fc engineering to impact the flexibility of route, schedule and dose for nearly any antibody.

20 Jan 2010

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it presented data from multiple pre-clinical and clinical programs at the “RNA Silencing: Mechanism, Biology, and Application” Keystone Symposium held January 14-19, 2010 in Keystone, Colorado. Alnylam and its collaborators presented data from Alnylam’s therapeutic programs including transthyretin (TTR)-mediated amyloidosis and Huntington’s disease, as well as new data on delivery approaches for the systemic delivery of RNAi therapeutics.

20 Jan 2010

iWorx launches a family of cardiovascular research products

iWorx, a developer of advanced physiology research and teaching tools, has launched a family of cardiovascular research products used to assess cardiac performance and hemodynamics, both in vivo and in vitro.

20 Jan 2010

Findings pave way for designing better antibiotics to target bacterial transcription machinery

A new study led by researchers at NYU Langone Medical Center is shedding new light on the action of Rho, a key regulatory protein in E. coli and many other bacteria.

19 Jan 2010

Axis Surgical Technologies completes evaluation of C-MOR orthopedic device

Axis Surgical Technologies, Inc., has announced the first evaluation in human patients of their lead product: a self-contained portable direct-imaging tool. The C-MOR™ functions much like a standard arthroscopic tower, yet at a fraction of both the size and cost.

18 Jan 2010

in vivo News and Research

Heart research news and updates from University of Houston

Injectable sealant found to be biocompatible and effective for fetal tissue repair

BioTech Medics begins creating TV and radio commercials for SHBAN Alcohol Free Antiseptic Hand Sanitizer

The American Journal of Pathology: Highlights from February 2010 issue

Researchers show how MRSA transmission can be tracked in hospital settings

Molecular image guided system for diagnosis and treatment of small-cell peripheral lung cancer

Study lays groundwork to develop new treatments for cardiovascular disease and other conditions

Growth of OMI equipment sales to reach $400M in 2014

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Australia issues patent covering Kane Biotech's DispersinB anti-biofilm technology

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

Copper-free version of click chemistry crafted to create biomolecular probes

New LNP compositions that improve systemic delivery of RNAi therapeutics discovered

InVivo Therapeutics sponsors fundraising event to support patients with spinal cord injuries

New pre-clinical data on RXi Pharmaceuticals' proprietary rxRNA compounds presented

Fc engineering enhances antibody half-life

Alnylam Pharmaceuticals presents data on multiple therapeutic programs at RNAi Symposium

iWorx launches a family of cardiovascular research products

Findings pave way for designing better antibiotics to target bacterial transcription machinery

Axis Surgical Technologies completes evaluation of C-MOR orthopedic device

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News